EsoGuard ® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment Conference call and webcast to be held today, August 12 th at 8:30 AM EDT NEW YORK , Aug. 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD ) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.
(Nasdaq: PAVM , PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended June 30, 2024 . Conference Call and Webcast The webcast will take place on Monday, August 12, 2024 , at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com .
Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785.
All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com .
Business Update Highlights "I am very pleased with the excellent progress Lucid has made on multiple fronts during the second quarter and .